In:
International Journal of Cancer, Wiley, Vol. 124, No. 12 ( 2009-06-15), p. 2829-2836
Abstract:
WWP1, a HECT type E3 ubiquitin ligase frequently amplified and overexpressed in breast cancer, has the potential to become a useful clinical biomarker and therapeutic target in breast cancer. Here, we performed immunohistochemical staining in formalin‐fixed and paraffin‐embedded tissue sections from 187 cases of primary invasive mammary carcinoma [137 ductal carcinomas (IDC) and 50 lobular carcinomas (ILC)] by using a monoclonal anti‐WWP1 antibody. The normal breast epithelium and adjacent benign epithelium are essentially negative for WWP1. Cytoplasmic WWP1 immunoreactivity was observed in 76/187 (40.6%) tumors and showed a positive correlation with ERα ( p = 0.05) and IGF‐1R proteins ( p = 0.001) in this cohort. The positive correlations between WWP1 and ER/IGF‐1R were also observed in a panel of 12 breast cancer cell lines by Western blot. Interestingly, the ER levels are decreased when WWP1 is silenced in ER positive MCF7 and T47D breast cancer cell lines. Finally, WWP1 ablation collectively inhibits cell proliferation with tamoxifen in MCF7 and T47D, as measured by 3 H‐thymidine incorporation assays. These findings suggest that WWP1 may play an important role in ER positive breast cancer. © 2009 UICC
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2009
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
